Northwest & Ethical Investments L.P. Has $9.17 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Northwest & Ethical Investments L.P. reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,615 shares of the medical research company’s stock after selling 5,143 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Thermo Fisher Scientific were worth $9,169,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Inceptionr LLC bought a new position in Thermo Fisher Scientific during the second quarter worth $667,000. Richmond Investment Services LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $249,000. J.W. Cole Advisors Inc. boosted its holdings in shares of Thermo Fisher Scientific by 135.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 9,026 shares of the medical research company’s stock worth $3,660,000 after buying an additional 5,198 shares during the period. North Star Asset Management Inc. raised its holdings in Thermo Fisher Scientific by 6.7% in the 2nd quarter. North Star Asset Management Inc. now owns 60,563 shares of the medical research company’s stock valued at $24,556,000 after acquiring an additional 3,824 shares during the period. Finally, Manchester Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.8% during the second quarter. Manchester Capital Management LLC now owns 2,308 shares of the medical research company’s stock worth $936,000 after acquiring an additional 41 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on TMO. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. UBS Group lifted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Finally, Barclays increased their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $65,247,057.48. This represents a 13.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michel Lagarde sold 4,638 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $594.42, for a total value of $2,756,919.96. Following the completion of the transaction, the chief operating officer owned 23,480 shares in the company, valued at approximately $13,956,981.60. This represents a 16.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 52,570 shares of company stock worth $30,382,352. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 0.7%

TMO opened at $593.41 on Thursday. The stock has a market capitalization of $222.95 billion, a price-to-earnings ratio of 34.28, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a 50-day simple moving average of $544.05 and a 200 day simple moving average of $477.35.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.